Completed OBSERVATIONAL NCT02333929

Validation of Rivaroxaban Assay for US Registration

Sponsor: Diagnostica Stago

Conditions Patients Receiving Rivaroxaban Treatment

Interventions STA- Rivaroxaban Calibrator&Control

Updated 11 times since 2017 Last updated: Feb 13, 2017 Started: Mar 31, 2015 Primary completion: Dec 31, 2016 Completion: Dec 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Patients Receiving Rivaroxaban Treatment, this trial is completed. The trial is conducted by Diagnostica Stago and has accumulated 11 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

11 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Dec 2021 — Jul 2024 [monthly]

Completed
Jan 2021 — Dec 2021 [monthly]

Completed
Nov 2020 — Jan 2021 [monthly]

Completed

▶ Show 6 earlier versions

Jun 2018 — Nov 2020 [monthly]

Completed
May 2018 — Jun 2018 [monthly]

Completed
Apr 2018 — May 2018 [monthly]

Completed

Phase: NA → None
Aug 2017 — Apr 2018 [monthly]

Completed NA
Feb 2017 — Aug 2017 [monthly]

Completed NA

Status: Unknown Status → Completed
Jan 2017 — Feb 2017 [monthly]

Unknown Status NA

First recorded

Mar 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Diagnostica Stago

Data source: Diagnostica Stago

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Allentown, United States